查詢結果分析
來源資料
相關文獻
- Patients Who Previously Responded to EGFR-TKI Treatment with Progression Responded to a Second EGFR-TKI Treatment after Challenge with Chemotherapy
- Recent Advances in Systemic Therapy for Non-Small Cell Lung Cancer in Elderly Patients
- 非小細胞肺癌的維持性治療
- 非小細胞肺癌標靶治療現況
- 非小細胞肺癌標靶藥物治療新進展
- 晚期非小細胞肺癌藥物治療現況與未來發展
- Gefitinib as First-Line Therapy for Advanced or Metastatic Non-Small Cell Lung Cancer Patients in Southern Taiwan
- Bortezomib-induced Apoptosis in the Treatment of Non-small Cell Lung Cancer
- 晚期非小細胞肺癌的標靶治療
- 非小細胞肺癌治療之風雲再起
頁籤選單縮合
| 題 名 | Patients Who Previously Responded to EGFR-TKI Treatment with Progression Responded to a Second EGFR-TKI Treatment after Challenge with Chemotherapy=之前使用過上皮細胞生長因子接受體-酪胺酸酶抑制劑有效的病患在疾病惡化後,再經過化學藥物治療一段時間後,仍有機會對再度使用上皮細胞生長因子接受體-酪胺酸酶抑制劑有效 |
|---|---|
| 作 者 | 陳育民; 蔡俊明; 李毓芹; 彭瑞鵬; 彭汪嘉康; | 書刊名 | 臺灣癌症醫學雜誌 |
| 卷 期 | 27:2 2011.04[民100.04] |
| 頁 次 | 頁62-70 |
| 分類號 | 415.468 |
| 關鍵詞 | 上皮細胞生長因子接受體-酪胺酸酶抑制劑; 非小細胞肺癌; 標靶治療; Epidermal growth factor receptor-tyrosine kinase inhibitor; Non-small-cell lung cancer; Targeted therapy; |
| 語 文 | 英文(English) |
| 中文摘要 | 我們報告三位曾經有效使用上皮細胞生長因子接受體-酪胺酸酶抑制劑(EGFR-TKI)於非小細胞肺癌病患,但後來病情惡化,再經過多次化療後,成功使用erlotinib治療病患的病例。其中一位病患有癌細胞的EGFR exon 19缺損,一位有exon 21的L858R突變,而另一位病患的EGFR有無突變則未知。三位病患均對初次使用EGFR-TKI有效,而在疾病惡化後,改用化學藥物治療。在經過多線化學藥物治療失敗或惡化後,他們再度使用erlotinib而且又有治療效果,並且有症狀與生活品質的改善。在各種使用EGFR-TKI與化學藥物治療失敗後的治療選擇中,重新使用EGFR-TKI,例如erlotinib,也可以嘗試於先前對EGFR-TKI有效的病患。 |
| 英文摘要 | We report three cases of successful re-treatment with erlotinib in non-small-cell lung cancer (NSCLC) patients whose disease progressed after previous epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) treatment and salvage chemotherapy. One had a tumor EGFR exon 19 deletion in initial diagnosis, one had an exon 21 L858R mutation, and the remaining one had an unknown EGFR mutation status. They all had a partial response to initial EGFR-TKI treatment, then, with disease progression the treatment was changed to chemotherapy. After several lines of salvage chemotherapy and disease progression, they then received single-agent erlotinib treatment and had a rapid response to the treatment, with improved quality of life and symptoms. Among the many salvage therapy options for patients with disease progression after EGFR-TKI treatment and chemotherapies, reuse of EGFR-TKI, such as erlotinib, may be tried for those patients who had a good initial response to EGFR-TKI treatment. |
本系統中英文摘要資訊取自各篇刊載內容。